spironolactone has been researched along with Diabetic Glomerulosclerosis in 72 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in subjects with diabetic kidney disease, albeit with a large variability between individuals." | 9.34 | Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. ( Hankemeier, T; Heerspink, HJL; Jacobsen, IA; Mehdi, UF; Mulder, S; Oxlund, C; Pena, MJ; Perco, P; Toto, R, 2020) |
| " Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial." | 9.24 | Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017) |
| "Our results indicate that the renoprotective effect of spironolactone when added to RAAS blockade is not mediated through anti-inflammatory pathways since markers of inflammation and endothelial dysfunction are not affected during treatment." | 9.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| "A double-blind, randomized, placebo-controlled crossover study in 21 patients with Type 1 diabetes and microalbuminuria using spironolactone 25 mg or placebo once daily, for 60 days added to standard antihypertensive treatment." | 9.16 | Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012) |
| "Addition of a modest dose of spironolactone to a regimen of ACEI or ARB in patients with diabetic proteinuria causes further reduction in proteinuria and also lowers the systolic BP." | 9.13 | Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. ( Gyebi, LK; Saklayen, MG; Tasosa, J; Yap, J, 2008) |
| "To study the effects of addition of spironolactone to angiotensin-converting enzyme (ACE) inhibition or angiotensin II (AngII) receptor antagonism on proteinuria, blood pressure (BP) and renal function in overt type 2 diabetic nephropathy." | 9.12 | Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. ( Baggen, RG; Boomsma, F; Lindemans, A; Pauli, S; Poldermans, D; van den Meiracker, AH; Vulto, AG, 2006) |
| "At the doses tested, spironolactone was superior to cilazapril in reducing albuminuria." | 9.11 | The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. ( Amit, M; Berla, M; Kedar, Y; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 2004) |
| "The addition of spironolactone to the combination of an ACE inhibitor, and ARB, and a direct renin inhibitor brought about dramatic and sustained reversal of 4-plus proteinuria in a patient with diabetes mellitus and hypertension." | 7.78 | Dramatic reduction of proteinuria in diabetic nephropathy by the use of spironolactone. ( Floyd, HW, 2012) |
| "Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial." | 6.72 | Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in subjects with diabetic kidney disease, albeit with a large variability between individuals." | 5.34 | Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. ( Hankemeier, T; Heerspink, HJL; Jacobsen, IA; Mehdi, UF; Mulder, S; Oxlund, C; Pena, MJ; Perco, P; Toto, R, 2020) |
| " Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial." | 5.24 | Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017) |
| " Steroidal mineralocorticoid receptor antagonists (MRAs - eplerenone and spironolactone) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF)." | 5.22 | Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. ( Armani, A; Caprio, M; Infante, M; Marzolla, V; Rizzo, M, 2022) |
| "In short-term studies in patients with CKD and reduced ejection heart failure, with or without T2D, finerenone 20 mg appears to have a better renal outcome compared with spironolactone and a better mortality outcome compared with eplerenone, with significantly lesser hyperkalemia compared to both spironolactone and finerenone." | 5.22 | Finerenone in diabetic kidney disease: A systematic review and critical appraisal. ( Misra, A; Singh, A; Singh, AK; Singh, R, 2022) |
| "Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy." | 5.20 | Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015) |
| "Our results indicate that the renoprotective effect of spironolactone when added to RAAS blockade is not mediated through anti-inflammatory pathways since markers of inflammation and endothelial dysfunction are not affected during treatment." | 5.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| "A double-blind, randomized, placebo-controlled crossover study in 21 patients with Type 1 diabetes and microalbuminuria using spironolactone 25 mg or placebo once daily, for 60 days added to standard antihypertensive treatment." | 5.16 | Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012) |
| " We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily)." | 5.14 | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. ( Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL, 2009) |
| " We sought to evaluate the effects of a three-month treatment with 25 mg spironolactone, an aldosterone receptor antagonist, on nephron function in 20 type II diabetic patients with persistent microalbuminuria, despite at least six months' use of an ACEi or ARB (combination group), and in eleven type II diabetic patients with persistent microalbuminuria who have never used an ACEi or an ARB (spironolactone group)." | 5.13 | The effects of spironolactone on nephron function in patients with diabetic nephropathy. ( Demirkan, B; Sut, N; Tugrul, A; Ustundag, A; Ustundag, S, 2008) |
| "Addition of a modest dose of spironolactone to a regimen of ACEI or ARB in patients with diabetic proteinuria causes further reduction in proteinuria and also lowers the systolic BP." | 5.13 | Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. ( Gyebi, LK; Saklayen, MG; Tasosa, J; Yap, J, 2008) |
| "To study the effects of addition of spironolactone to angiotensin-converting enzyme (ACE) inhibition or angiotensin II (AngII) receptor antagonism on proteinuria, blood pressure (BP) and renal function in overt type 2 diabetic nephropathy." | 5.12 | Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. ( Baggen, RG; Boomsma, F; Lindemans, A; Pauli, S; Poldermans, D; van den Meiracker, AH; Vulto, AG, 2006) |
| " In this study, we explored the effects of the mineralocorticoid receptor antagonist spironolactone on urinary protein excretion in patients with chronic renal disease with proteinuria persistently more than 0." | 5.11 | Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. ( Hayashi, K; Saruta, T; Sato, A, 2005) |
| "At the doses tested, spironolactone was superior to cilazapril in reducing albuminuria." | 5.11 | The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. ( Amit, M; Berla, M; Kedar, Y; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 2004) |
| "Among patients with DKD and hypertension, the short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy." | 4.02 | Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. ( An, J; Niu, F; Sim, JJ, 2021) |
| "Although matching aligned key demographic and clinical characteristics of the cohorts, a significantly greater proportion of spironolactone users than non-users had oedema, proteinuria, and cardiovascular disease at baseline (P < 0." | 3.96 | Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users. ( Blankenburg, M; Fett, AK; Gay, A; Griner, RG; Kovesdy, CP, 2020) |
| "The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors." | 3.78 | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. ( Hosoya, T; Ishii, T; Kawamura, T; Okonogi, H; Tsuboi, N, 2012) |
| "The addition of spironolactone to the combination of an ACE inhibitor, and ARB, and a direct renin inhibitor brought about dramatic and sustained reversal of 4-plus proteinuria in a patient with diabetes mellitus and hypertension." | 3.78 | Dramatic reduction of proteinuria in diabetic nephropathy by the use of spironolactone. ( Floyd, HW, 2012) |
| "Streptozotocin-induced renal fibrosis, PAI-1 expression, TGF-beta1 expression, and macrophage infiltration occur via mineralocorticoid receptor, and spironolactone ameliorates renal fibrosis presumably via the inhibition of macrophage infiltration, PAI-1 expression, and TGF-beta1 expression in streptozotocin-induced early diabetic injury." | 3.72 | Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2004) |
| "Our results indicate high-dose irbesartan combined with spironolactone may be more efficient in reducing UAER in elderly patients with early DN, but this treatment could cause hyperkalemia." | 2.87 | Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018) |
| " We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN)." | 2.82 | Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. ( Adams-Huet, B; Srivastava, A; Toto, RD; Vega, GL, 2016) |
| "Small diabetic kidney disease (DKD) clinical studies demonstrate that steroidal MRAs reduce albuminuria relative to placebo, although hyperkalemia is a major adverse event that has precluded large outcome trials." | 2.82 | Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. ( Bakris, GL; Cohen, S; Sternlicht, H, 2022) |
| "Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial." | 2.72 | Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "Spironolactone treatment induced an insignificant reversible reduction in GFR of 3 ml/min per 1." | 2.71 | Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. ( Boomsma, F; Parving, HH; Rossing, K; Schjoedt, KJ; Smidt, UM, 2005) |
| "Aldosterone has been suggested to play a role in the initiation and progression of diabetic nephropathy." | 2.71 | Beneficial impact of spironolactone in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2005) |
| "It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape)." | 2.71 | Effectiveness of aldosterone blockade in patients with diabetic nephropathy. ( Hayashi, K; Naruse, M; Saruta, T; Sato, A, 2003) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the western world." | 2.47 | The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone. ( Schjoedt, KJ, 2011) |
| "Diabetic nephropathy is one of the most common causes of end-stage kidney disease." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "TLR4 may participate in the progress of diabetic nephropathy." | 1.36 | [Effect of spironolactone on the expression of Toll-like receptor 4 in renal tubular epithelia cells exposed to high glucose]. ( Ao, X; Bao, RL; Hong, XM; Liu, KH; Tang, TF; Zhou, QL, 2010) |
| "Spironolactone can inhibit high glucose-induced renal tubular epithelial cells EMT, which may be an important mechanism for the inhibition of renal interstitial fibrosis." | 1.36 | [Effect of aldosterone and its antagonist spironolactone on epithelial-mesenchymal transition of normal rat kidney epithelial cells in high glucose]. ( Ao, X; Hong, X; Liu, K; Pouranan, V; Xiao, Z; Yuan, M; Zhou, Q, 2010) |
| "Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure." | 1.33 | Role of aldosterone in diabetic nephropathy. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS, 2005) |
| "Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis." | 1.33 | Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, CH; Kim, HK; Kim, HS; Kim, YS; Lee, MH; Song, HK, 2006) |
| "Spironolactone treatment did not induce any significant differences in body weight, kidney/body weight ratio, serum creatinine concentration, blood glucose levels, or systolic blood pressure." | 1.33 | Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS; Lee, MH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (33.33) | 29.6817 |
| 2010's | 35 (48.61) | 24.3611 |
| 2020's | 10 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Piotrowski, DW | 1 |
| An, J | 1 |
| Niu, F | 1 |
| Sim, JJ | 1 |
| Ghaffari, T | 1 |
| Moradi, N | 2 |
| Chamani, E | 2 |
| Ebadi, Z | 2 |
| Fadaei, R | 2 |
| Alizadeh-Fanalou, S | 1 |
| Yarahmadi, S | 1 |
| Fallah, S | 2 |
| Cohen, S | 1 |
| Sternlicht, H | 1 |
| Bakris, GL | 2 |
| Marzolla, V | 1 |
| Infante, M | 1 |
| Armani, A | 1 |
| Rizzo, M | 1 |
| Caprio, M | 1 |
| Singh, AK | 1 |
| Singh, A | 1 |
| Singh, R | 1 |
| Misra, A | 1 |
| Ding, K | 1 |
| Li, Z | 2 |
| Lu, Y | 1 |
| Sun, L | 1 |
| Kazemi Fard, T | 1 |
| Balochnejadmojarrad, T | 1 |
| Blankenburg, M | 1 |
| Kovesdy, CP | 1 |
| Fett, AK | 1 |
| Griner, RG | 1 |
| Gay, A | 1 |
| Nicholas, SB | 1 |
| Mulder, S | 1 |
| Perco, P | 1 |
| Oxlund, C | 2 |
| Mehdi, UF | 2 |
| Hankemeier, T | 1 |
| Jacobsen, IA | 2 |
| Toto, R | 1 |
| Heerspink, HJL | 1 |
| Pena, MJ | 1 |
| Rico-Mesa, JS | 1 |
| White, A | 1 |
| Ahmadian-Tehrani, A | 1 |
| Anderson, AS | 1 |
| Dojki, FK | 1 |
| Bakris, G | 1 |
| Chen, Y | 2 |
| Liu, P | 1 |
| Chen, X | 1 |
| Li, Y | 1 |
| Zhang, F | 1 |
| Wang, Y | 1 |
| Pitt, B | 2 |
| Weir, MR | 1 |
| Freeman, MW | 1 |
| Lainscak, M | 1 |
| Mayo, MR | 1 |
| Garza, D | 1 |
| Zawadzki, R | 1 |
| Berman, L | 1 |
| Bushinsky, DA | 1 |
| Koszegi, S | 1 |
| Molnar, A | 1 |
| Lenart, L | 1 |
| Hodrea, J | 1 |
| Balogh, DB | 1 |
| Lakat, T | 1 |
| Szkibinszkij, E | 1 |
| Hosszu, A | 1 |
| Sparding, N | 1 |
| Genovese, F | 1 |
| Wagner, L | 1 |
| Vannay, A | 1 |
| Szabo, AJ | 1 |
| Fekete, A | 1 |
| Dong, D | 1 |
| Fan, TT | 1 |
| Ji, YS | 1 |
| Yu, JY | 1 |
| Wu, S | 1 |
| Zhang, L | 2 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Esteghamati, A | 1 |
| Noshad, S | 1 |
| Jarrah, S | 1 |
| Mousavizadeh, M | 1 |
| Khoee, SH | 1 |
| Nakhjavani, M | 1 |
| Mavrakanas, TA | 2 |
| Gariani, K | 1 |
| Martin, PY | 1 |
| Van Buren, PN | 1 |
| Adams-Huet, B | 3 |
| Nguyen, M | 1 |
| Molina, C | 1 |
| Toto, RD | 3 |
| Seliger, SL | 1 |
| Fried, LF | 1 |
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| Kato, S | 1 |
| Maruyama, S | 1 |
| Makino, H | 1 |
| Wada, J | 1 |
| Ogawa, D | 1 |
| Uzu, T | 1 |
| Araki, H | 1 |
| Koya, D | 1 |
| Kanasaki, K | 1 |
| Oiso, Y | 1 |
| Goto, M | 1 |
| Nishiyama, A | 1 |
| Kobori, H | 1 |
| Imai, E | 1 |
| Ando, M | 1 |
| Matsuo, S | 1 |
| Hou, J | 1 |
| Xiong, W | 1 |
| Cao, L | 1 |
| Wen, X | 1 |
| Li, A | 1 |
| Shi, W | 1 |
| Zhang, H | 1 |
| Liu, S | 1 |
| Liang, X | 1 |
| Ling, T | 1 |
| Yu, C | 1 |
| Huang, Z | 1 |
| Tan, X | 1 |
| Zhao, X | 1 |
| Ye, Z | 1 |
| Zhang, B | 1 |
| Wang, W | 1 |
| Li, R | 1 |
| Ma, J | 1 |
| Wang, S | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Cui, W | 1 |
| Miao, L | 1 |
| Li, D | 1 |
| Lu, Z | 1 |
| Xu, Z | 1 |
| Ji, J | 1 |
| Zheng, Z | 1 |
| Lin, S | 1 |
| Yan, T | 1 |
| Srivastava, A | 1 |
| Vega, GL | 2 |
| Kolkhof, P | 1 |
| Jaisser, F | 1 |
| Kim, SY | 1 |
| Filippatos, G | 1 |
| Nowack, C | 1 |
| Kurt, B | 1 |
| Schwarzensteiner, I | 1 |
| Hansen, MR | 1 |
| Stæhr, M | 1 |
| Svenningsen, P | 1 |
| Hansen, PB | 1 |
| Thuesen, AD | 1 |
| Toft, A | 1 |
| Hinrichs, GR | 1 |
| Bistrup, C | 1 |
| Jensen, BL | 1 |
| Taira, M | 1 |
| Toba, H | 2 |
| Murakami, M | 1 |
| Iga, I | 1 |
| Serizawa, R | 2 |
| Murata, S | 1 |
| Kobara, M | 2 |
| Nakata, T | 2 |
| Kang, YS | 4 |
| Ko, GJ | 1 |
| Lee, MH | 3 |
| Song, HK | 2 |
| Han, SY | 4 |
| Han, KH | 4 |
| Kim, HK | 4 |
| Han, JY | 4 |
| Cha, DR | 4 |
| Ustundag, A | 1 |
| Tugrul, A | 1 |
| Ustundag, S | 1 |
| Sut, N | 1 |
| Demirkan, B | 1 |
| Raskin, P | 1 |
| Liu, K | 2 |
| Zhou, Q | 2 |
| Ao, X | 2 |
| Pouranan, V | 2 |
| Hong, X | 1 |
| Xiao, Z | 2 |
| Yuan, M | 2 |
| Liu, KH | 1 |
| Zhou, QL | 1 |
| Tang, TF | 1 |
| Hong, XM | 1 |
| Bao, RL | 1 |
| Mitani, T | 1 |
| Takahashi, T | 1 |
| Imai, N | 1 |
| Wang, J | 1 |
| Cheva, A | 1 |
| Kallaras, K | 1 |
| Karkavelas, G | 1 |
| Mironidou-Tzouveleki, M | 1 |
| Kristensen, KE | 1 |
| Egfjord, M | 1 |
| Schjoedt, KJ | 5 |
| Tsuboi, N | 1 |
| Kawamura, T | 1 |
| Okonogi, H | 1 |
| Ishii, T | 1 |
| Hosoya, T | 1 |
| Lian, M | 1 |
| Hewitson, TD | 1 |
| Wigg, B | 1 |
| Samuel, CS | 1 |
| Chow, F | 1 |
| Becker, GJ | 1 |
| Takata, H | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Cheng, Y | 1 |
| Yoneda, T | 1 |
| Demura, M | 1 |
| Yagi, K | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Pessôa, BS | 1 |
| Peixoto, EB | 1 |
| Papadimitriou, A | 1 |
| Lopes de Faria, JM | 1 |
| Lopes de Faria, JB | 1 |
| Nielsen, SE | 2 |
| Persson, F | 2 |
| Frandsen, E | 1 |
| Sugaya, T | 1 |
| Hess, G | 1 |
| Zdunek, D | 1 |
| Shjoedt, KJ | 1 |
| Parving, HH | 5 |
| Rossing, P | 4 |
| Wu, H | 1 |
| Chen, L | 1 |
| Peng, W | 1 |
| Xiang, A | 1 |
| Tang, R | 1 |
| Zhang, W | 1 |
| Rossing, K | 4 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Floyd, HW | 1 |
| Sato, A | 2 |
| Hayashi, K | 2 |
| Naruse, M | 1 |
| Saruta, T | 2 |
| Rachmani, R | 1 |
| Slavachevsky, I | 1 |
| Amit, M | 1 |
| Levi, Z | 1 |
| Kedar, Y | 1 |
| Berla, M | 1 |
| Ravid, M | 1 |
| Nitta, K | 1 |
| Uchida, K | 1 |
| Nihei, H | 1 |
| Fujisawa, G | 1 |
| Okada, K | 1 |
| Muto, S | 1 |
| Fujita, N | 1 |
| Itabashi, N | 1 |
| Kusano, E | 1 |
| Ishibashi, S | 1 |
| Smidt, UM | 1 |
| Boomsma, F | 4 |
| Jee, YH | 3 |
| Kim, YS | 3 |
| Juhl, TR | 2 |
| Tarnow, L | 2 |
| Takebayashi, K | 2 |
| Matsumoto, S | 2 |
| Aso, Y | 2 |
| Inukai, T | 1 |
| Kim, CH | 1 |
| Kim, HS | 1 |
| Guo, C | 1 |
| Martinez-Vasquez, D | 1 |
| Mendez, GP | 1 |
| Toniolo, MF | 1 |
| Yao, TM | 1 |
| Oestreicher, EM | 1 |
| Kikuchi, T | 1 |
| Lapointe, N | 1 |
| Pojoga, L | 1 |
| Williams, GH | 1 |
| Ricchiuti, V | 1 |
| Adler, GK | 2 |
| Epstein, M | 1 |
| Campese, VM | 1 |
| Park, J | 1 |
| van den Meiracker, AH | 1 |
| Baggen, RG | 1 |
| Pauli, S | 1 |
| Lindemans, A | 1 |
| Vulto, AG | 1 |
| Poldermans, D | 1 |
| Joffe, HV | 1 |
| Kwong, RY | 1 |
| Gerhard-Herman, MD | 1 |
| Rice, C | 1 |
| Feldman, K | 1 |
| Yuan, J | 1 |
| Jia, R | 1 |
| Bao, Y | 1 |
| Saklayen, MG | 1 |
| Gyebi, LK | 1 |
| Tasosa, J | 1 |
| Yap, J | 1 |
| Herman, E | 2 |
| Radó, J | 2 |
| Tourniaire, J | 1 |
| Bajard, L | 1 |
| Harfouch, M | 1 |
| Rebattu, B | 1 |
| Garrel, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease[NCT03819153] | Phase 3 | 3,508 participants (Anticipated) | Interventional | 2019-06-17 | Active, not recruiting | ||
| A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and[NCT01371747] | Phase 2 | 324 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Improving Outcomes in Diabetic Nephropathy[NCT00381134] | Phase 2 | 92 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Spironolactone in Diabetic Nephropathy[NCT00317954] | Phase 4 | 48 participants | Interventional | 2003-09-30 | Completed | ||
| Aldosterone and Vascular Disease in Diabetes Mellitus[NCT00214825] | 46 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| Spironolactone for Reducing Proteinuria in Diabetic Nephropathy[NCT00498537] | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Day 3
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.26 |
| Stratum 1: 16.8 g/d Patiromer | -0.28 |
| Stratum 1: 25.2 g/d Patiromer | -0.31 |
| Stratum 2: 16.8 g/d Patiromer | -0.65 |
| Stratum 2: 25.2 g/d Patiromer | -0.59 |
| Stratum 2: 33.6 g/d Patiromer | -0.53 |
Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.51 |
| Stratum 1: 25.2 g/d Patiromer | -0.55 |
| Stratum 2: 16.8 g/d Patiromer | -0.87 |
| Stratum 2: 25.2 g/d Patiromer | -0.97 |
| Stratum 2: 33.6 g/d Patiromer | -0.92 |
Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.47 |
| Stratum 1: 25.2 g/d Patiromer | -0.54 |
| Stratum 2: 16.8 g/d Patiromer | -0.88 |
| Stratum 2: 25.2 g/d Patiromer | -0.95 |
| Stratum 2: 33.6 g/d Patiromer | -0.91 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.54 |
| Stratum 1: 16.8 g/d Patiromer | -0.44 |
| Stratum 1: 25.2 g/d Patiromer | -0.50 |
| Stratum 2: 16.8 g/d Patiromer | -1.00 |
| Stratum 2: 25.2 g/d Patiromer | -0.96 |
| Stratum 2: 33.6 g/d Patiromer | -1.17 |
(NCT01371747)
Timeframe: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 0.36 |
| Stratum 1: 16.8 g/d Patiromer | 0.22 |
| Stratum 1: 25.2 g/d Patiromer | 0.30 |
| Stratum 2: 16.8 g/d Patiromer | 0.41 |
| Stratum 2: 25.2 g/d Patiromer | 0.39 |
| Stratum 2: 33.6 g/d Patiromer | 0.58 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 100 |
| Stratum 1: 16.8 g/d Patiromer | 100 |
| Stratum 1: 25.2 g/d Patiromer | 98.4 |
| Stratum 2: 16.8 g/d Patiromer | 91.7 |
| Stratum 2: 25.2 g/d Patiromer | 95.8 |
| Stratum 2: 33.6 g/d Patiromer | 95.5 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 95.2 |
| Stratum 1: 16.8 g/d Patiromer | 90.8 |
| Stratum 1: 25.2 g/d Patiromer | 81.3 |
| Stratum 2: 16.8 g/d Patiromer | 79.2 |
| Stratum 2: 25.2 g/d Patiromer | 91.7 |
| Stratum 2: 33.6 g/d Patiromer | 77.3 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 86.3 |
| Stratum 1: 16.8 g/d Patiromer | 81.6 |
| Stratum 1: 25.2 g/d Patiromer | 88.9 |
| Stratum 2: 16.8 g/d Patiromer | 86.7 |
| Stratum 2: 25.2 g/d Patiromer | 89.5 |
| Stratum 2: 33.6 g/d Patiromer | 93.3 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | Days (Median) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 4 |
| Stratum 1: 16.8 g/d Patiromer | 4 |
| Stratum 1: 25.2 g/d Patiromer | 4 |
| Stratum 2: 16.8 g/d Patiromer | 8 |
| Stratum 2: 25.2 g/d Patiromer | 7.5 |
| Stratum 2: 33.6 g/d Patiromer | 8 |
12 reviews available for spironolactone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Drug Design; Humans; Hypertension; Mineralocorticoid Receptor Antag | 2012 |
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Female; Glucagon-Like Peptide-1 Receptor; Humans; Male; M | 2022 |
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; H | 2022 |
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Topics: Diabetic Nephropathies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridine | 2020 |
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
Topics: Albuminuria; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone | 2017 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Ne | 2014 |
Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetic Nephropathies; Disease Pr | 2015 |
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
Topics: Animals; Anthocyanins; Antibodies, Monoclonal; Connective Tissue Growth Factor; Diabetes Mellitus; D | 2015 |
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Topics: Animals; Cardio-Renal Syndrome; Diabetic Nephropathies; Endothelial Cells; Eplerenone; Fibroblasts; | 2017 |
The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyto | 2011 |
23 trials available for spironolactone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans | 2020 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2018 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetic | 2013 |
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
Topics: Adult; Aged; Albuminuria; Aldosterone; Asian People; Blood Pressure; Diabetes Mellitus, Type 2; Diab | 2015 |
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.
Topics: Diabetic Nephropathies; Female; Humans; Lipoproteins; Losartan; Male; Middle Aged; Spironolactone; T | 2016 |
Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.
Topics: Adult; Aged; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Diabetic Nephropathies; Fem | 2017 |
The effects of spironolactone on nephron function in patients with diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2008 |
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Angiotens | 2012 |
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; End | 2013 |
Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab | 2003 |
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.
Topics: Aged; Albuminuria; Blood Pressure; Cilazapril; Creatinine; Diabetic Nephropathies; Drug Therapy, Com | 2004 |
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Collagen Type IV; Diabetes Mellitus, | 2005 |
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Cross-Over Studies; Diabetic N | 2005 |
Beneficial impact of spironolactone in diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2005 |
Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy.
Topics: Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Humans; Mineralocortic | 2006 |
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2006 |
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
Topics: Adiponectin; Aged; Body Mass Index; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2006 |
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachia | 2007 |
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 2008 |
37 other studies available for spironolactone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardi | 2021 |
Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33.
Topics: Animals; ATP Binding Cassette Transporter 1; Captopril; Diabetes Mellitus, Experimental; Diabetic Ne | 2022 |
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2023 |
Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting microRNA-192 and microRNA-29a/b/c.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Urea Nitrogen; Captopril; Creatinine; Diabete | 2019 |
Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users.
Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dise | 2020 |
Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Disease Progression; Humans; Prospective Studies; Proteom | 2020 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin | 2019 |
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me | 2019 |
Serum potassium in dual renin-angiotensin-aldosterone system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions.
Topics: Animals; Cell Line; Cell Movement; Diabetic Nephropathies; Gene Expression Regulation; Glucose; Inte | 2015 |
Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress.
Topics: Autophagy; Autophagy-Related Protein 5; Cell Adhesion; Cell Line; Chromones; Diabetic Nephropathies; | 2016 |
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Topics: Animals; Collagen Type I; Collagen Type IV; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Experimenta | 2008 |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Collagen Type IV; Dia | 2009 |
[Effect of aldosterone and its antagonist spironolactone on epithelial-mesenchymal transition of normal rat kidney epithelial cells in high glucose].
Topics: Aldosterone; Animals; Cell Differentiation; Cell Line; Cells, Cultured; Diabetic Nephropathies; Epit | 2010 |
[Effect of spironolactone on the expression of Toll-like receptor 4 in renal tubular epithelia cells exposed to high glucose].
Topics: Cells, Cultured; Diabetic Nephropathies; Epithelial Cells; Humans; Hyperglycemia; Immunohistochemist | 2010 |
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropat | 2010 |
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Creatinine; Diabetes Mellitus, Experimental; Diab | 2010 |
[Aldosterone exacerbates chronic renal insufficiency].
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2011 |
The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
Topics: Adult; Aged; Blood Pressure; Diabetic Nephropathies; Eplerenone; Female; Glomerular Filtration Rate; | 2012 |
Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen Type IV; Diabetes Mellitus, Experi | 2012 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat.
Topics: Animals; Antioxidants; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; DNA Dama | 2012 |
Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.
Topics: Acute Kidney Injury; Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2012 |
Dramatic reduction of proteinuria in diabetic nephropathy by the use of spironolactone.
Topics: Diabetic Nephropathies; Diuretics; Humans; Male; Middle Aged; Proteinuria; Spironolactone | 2012 |
Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases.
Topics: Angiotensin Receptor Antagonists; Diabetic Nephropathies; Female; Humans; Kidney Diseases; Male; Mid | 2004 |
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Immunohisto | 2004 |
Role of aldosterone in diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Animals; Cells, Cultured; Chemokine CCL2; Collagen; Connective Tissue Grow | 2005 |
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabe | 2006 |
Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Collagen Type IV; Connective Tissue Gro | 2006 |
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2006 |
Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2006 |
Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2006 |
Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glutathione Peroxida | 2007 |
[Hyperkalemia with fatal paralysis in a diabetic patient treated with aldactone].
Topics: Adult; Diabetic Nephropathies; Humans; Hyperkalemia; Male; Paralysis; Spironolactone | 1967 |
[Restoration of insulin sensitivity after correction of hypokalemia due to chronic tubulopathy in a diabetic patient].
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucose Clamp Technique; Humans; H | 1988 |
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Topics: Adult; Diabetes Mellitus; Diabetic Nephropathies; Edema; Heart Failure; Humans; Hyperkalemia; Hypert | 1966 |